Research programme: beta-amyloid secretion inhibitors - Chiesi

Drug Profile

Research programme: beta-amyloid secretion inhibitors - Chiesi

Alternative Names: CHF 4801; CHF 5022; CHF-5077; CHF5096; CHF5105; β-amyloid secretion inhibitors

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi
  • Class Biphenyl compounds; Propionic acids
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Italy
  • 21 Jul 2006 Data presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2006) have been added to the pharmacokinetics and Alzheimer's Disease and Cognition Disorders pharmacodynamics sections
  • 07 Sep 2004 Data presented at the XVIIIth International Symposium on Medicinal Chemistry (ISMC-2004) have been added to the pharmacokinetics and Alzheimer's disease pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top